BRPI0506721A - composto ou um sal de adição de ácido do mesmo - Google Patents

composto ou um sal de adição de ácido do mesmo

Info

Publication number
BRPI0506721A
BRPI0506721A BRPI0506721-9A BRPI0506721A BRPI0506721A BR PI0506721 A BRPI0506721 A BR PI0506721A BR PI0506721 A BRPI0506721 A BR PI0506721A BR PI0506721 A BRPI0506721 A BR PI0506721A
Authority
BR
Brazil
Prior art keywords
acid addition
addition salt
compound
symptoms
useful
Prior art date
Application number
BRPI0506721-9A
Other languages
English (en)
Inventor
Robert Dean Dally
Jeffrey Alan Dodge
Scott Alan Frank
Ronald Jay Hinklin
Timothy Alan Shepherd
Owen Brendan Wallace
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of BRPI0506721A publication Critical patent/BRPI0506721A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/084—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/092—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings with aromatic radicals attached to the chain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/084—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/088—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04—Ortho- or peri-condensed ring systems
    • C07D221/18—Ring systems of four or more rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/78—Ring systems having three or more relevant rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D335/00—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom
    • C07D335/04—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

COMPOSTO OU UM SAL DE ADIçãO DE áCIDO DO MESMO A presente invenção está relacionada a modulador de receptor de estrogeno seletivo com a fórmula I ou Ia: (I)(Ia); ou um sal de adição de ácido, farmacêutico, do mesmo; útil para o tratamento de sintomas vasomotores, em particular surtos de calor, suores noturnos e outros sintomas que afetam as mulheres em torno da menopausa.
BRPI0506721-9A 2004-01-22 2005-01-18 composto ou um sal de adição de ácido do mesmo BRPI0506721A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US53834204P 2004-01-22 2004-01-22
US53844204P 2004-01-22 2004-01-22
PCT/US2005/000020 WO2005073204A1 (en) 2004-01-22 2005-01-18 Selective estrogen receptor modulators for the treatment of vasomotor symptoms

Publications (1)

Publication Number Publication Date
BRPI0506721A true BRPI0506721A (pt) 2007-05-02

Family

ID=34830456

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0506721-9A BRPI0506721A (pt) 2004-01-22 2005-01-18 composto ou um sal de adição de ácido do mesmo

Country Status (20)

Country Link
US (2) US20090023917A1 (pt)
EP (1) EP1709021B1 (pt)
JP (1) JP4909086B2 (pt)
KR (2) KR101008804B1 (pt)
CN (1) CN102250042A (pt)
AT (1) ATE476428T1 (pt)
AU (1) AU2005207821B2 (pt)
BR (1) BRPI0506721A (pt)
CA (1) CA2551956C (pt)
CR (1) CR8517A (pt)
DE (1) DE602005022673D1 (pt)
EA (2) EA016613B1 (pt)
EC (1) ECSP066711A (pt)
ES (1) ES2347973T3 (pt)
IL (1) IL176738A0 (pt)
MA (1) MA28436B1 (pt)
NO (1) NO20063760L (pt)
SG (1) SG149867A1 (pt)
UA (1) UA85862C2 (pt)
WO (1) WO2005073204A1 (pt)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2656067C (en) 2006-06-23 2014-08-12 Radius Health, Inc. Treatment of vasomotor symptoms with selective estrogen receptor modulators
US10144736B2 (en) * 2006-07-20 2018-12-04 Gilead Sciences, Inc. Substituted pteridines useful for the treatment and prevention of viral infections
US20100087402A1 (en) * 2008-09-29 2010-04-08 Vivus, Inc. Methods and compositions for the treatment of estrogen-dependent hyperproliferative uterine disorders
JP5548205B2 (ja) * 2008-09-29 2014-07-16 イーライ リリー アンド カンパニー 選択的エストロゲン受容体調節因子
US20100317635A1 (en) 2009-06-16 2010-12-16 Endorecherche, Inc. Treatment of hot flushes, vasomotor symptoms, and night sweats with sex steroid precursors in combination with selective estrogen receptor modulators
PL2568806T3 (pl) 2010-05-12 2017-03-31 Radius Health, Inc. Schematy lecznicze
WO2012047617A1 (en) 2010-09-28 2012-04-12 Radius Health, Inc. Selective androgen receptor modulators
FR3014437B1 (fr) * 2013-12-05 2016-12-23 Servier Lab Nouveau procede de synthese de l'agomelatine
FR3014434B1 (fr) * 2013-12-05 2015-12-25 Servier Lab Nouveau procede de synthese du 7-methoxy-naphtalene-1-carbaldehyde et application a la synthese de l'agomelatine
FI3122426T3 (fi) 2014-03-28 2023-03-31 Univ Duke Rintasyövän hoitaminen käyttäen selektiivisiä estrogeenin reseptorin modulaattoreita
US9421264B2 (en) 2014-03-28 2016-08-23 Duke University Method of treating cancer using selective estrogen receptor modulators
UA123090C2 (uk) 2015-03-04 2021-02-17 Гіліад Сайєнсіз, Інк. 4,6-ДІАМІНОПІРИДО[3,2-d]ПІРИМІДИНОВІ СПОЛУКИ, ЯКІ МОДУЛЮЮТЬ TOLL-ПОДІБНІ РЕЦЕПТОРИ
PL3474841T3 (pl) 2016-06-22 2022-07-11 Ellipses Pharma Ltd Sposoby leczenia nowotworu złośliwego piersi ar+
WO2018045150A1 (en) 2016-09-02 2018-03-08 Gilead Sciences, Inc. 4,6-diamino-pyrido[3,2-d]pyrimidine derivaties as toll like receptor modulators
EP3507276B1 (en) 2016-09-02 2021-11-03 Gilead Sciences, Inc. Toll like receptor modulator compounds
AU2018205285C9 (en) 2017-01-05 2024-05-23 Radius Pharmaceuticals, Inc. Polymorphic forms of RAD1901-2HCl
CN108675999B (zh) * 2018-05-09 2021-03-16 浙江农林大学暨阳学院 一种醋酸铜催化制备8-(9-亚砜基-10-二氢菲)喹啉类化合物的方法
CA3104395A1 (en) 2018-07-04 2020-01-09 Radius Pharmaceuticals, Inc. Polymorphic forms of rad1901-2hcl
PL3820874T3 (pl) * 2018-07-12 2023-02-06 Eli Lilly And Company Selektywne środki degradujące receptor estrogenowy
TWI702219B (zh) 2018-07-12 2020-08-21 美商美國禮來大藥廠 選擇性雌激素受體降解劑
TWI751517B (zh) 2019-04-17 2022-01-01 美商基利科學股份有限公司 類鐸受體調節劑之固體形式
TW202210480A (zh) 2019-04-17 2022-03-16 美商基利科學股份有限公司 類鐸受體調節劑之固體形式
TW202115056A (zh) 2019-06-28 2021-04-16 美商基利科學股份有限公司 類鐸受體調節劑化合物的製備方法
TW202300492A (zh) 2021-03-16 2023-01-01 美商美國禮來大藥廠 選擇性雌激素受體降解劑
US11926634B2 (en) 2022-02-01 2024-03-12 Eli Lilly And Company Processes for the preparation of selective estrogen receptor degraders

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5998401A (en) * 1995-02-28 1999-12-07 Eli Lilly And Company Naphthyl compounds, intermediates, compositions, and methods
US5726186A (en) * 1995-09-08 1998-03-10 Eli Lilly And Company Pentacyclic compounds, intermediates, processes, compositions, and methods
ID19392A (id) * 1996-08-29 1998-07-09 Lilly Co Eli Senyawa naftil dan bahan pertengahan serta komposisi dan metode penggunaan
CA2213810C (en) * 1996-08-29 2006-06-06 Lewis Dale Pennington Benzo¬b|thiophene compounds, intermediates, processes, compositions and methods
US5916916A (en) * 1996-10-10 1999-06-29 Eli Lilly And Company 1-aryloxy-2-arylnaphthyl compounds, intermediates, compositions, and methods
CA2217810A1 (en) * 1996-10-10 1998-04-10 Eli Lilly And Company 2-aryl-3-aminoaryloxynaphthyl compounds, intermediates, compositions and methods
JP2001513501A (ja) * 1997-08-07 2001-09-04 イーライ・リリー・アンド・カンパニー エストロゲン阻害活性を有する１−［４−（置換アルコキシ）ベンジル］ナフタレン化合物
NZ537138A (en) * 2002-07-22 2007-11-30 Lilly Co Eli Selective estrogen receptor modulators containing a phenylsulfonyl group

Also Published As

Publication number Publication date
JP2007519721A (ja) 2007-07-19
IL176738A0 (en) 2006-10-31
DE602005022673D1 (de) 2010-09-16
WO2005073204A1 (en) 2005-08-11
KR100849559B1 (ko) 2008-07-31
EP1709021A1 (en) 2006-10-11
ATE476428T1 (de) 2010-08-15
CR8517A (es) 2006-12-01
US20090023917A1 (en) 2009-01-22
AU2005207821A1 (en) 2005-08-11
ES2347973T3 (es) 2010-11-26
KR101008804B1 (ko) 2011-01-14
KR20080016755A (ko) 2008-02-21
ECSP066711A (es) 2006-10-31
EA016613B1 (ru) 2012-06-29
CA2551956C (en) 2013-05-07
EA012262B1 (ru) 2009-08-28
US8217032B2 (en) 2012-07-10
CN102250042A (zh) 2011-11-23
NO20063760L (no) 2006-10-16
JP4909086B2 (ja) 2012-04-04
EP1709021B1 (en) 2010-08-04
EA200601353A1 (ru) 2007-02-27
CA2551956A1 (en) 2005-08-11
US20110281847A1 (en) 2011-11-17
KR20060129277A (ko) 2006-12-15
MA28436B1 (fr) 2007-02-01
EA200900586A1 (ru) 2009-08-28
SG149867A1 (en) 2009-02-27
AU2005207821B2 (en) 2011-02-10
UA85862C2 (uk) 2009-03-10

Similar Documents

Publication Publication Date Title
BRPI0506721A (pt) composto ou um sal de adição de ácido do mesmo
BR0312675A (pt) Composto ou um sal de adição de ácido farmacêutico do mesmo,m e, métodos para tratar endometriose, e para tratar leiomioma uterino
ATE548039T1 (de) Kondensierte heteroarylpyridyl- und phenylbenzensulfonamide als ccr2-modulatoren zur behandlung von entzündungen
ATE555105T1 (de) Heterocyclische fxr-bindende verbindungen
EA200901157A1 (ru) Конденсированные кольцевые гетероциклические модуляторы киназы
EA200870193A1 (ru) Цитотоксические агенты, включающие новые производные томаймицина, и их терапевтическое применение
ATE469895T1 (de) Cgrp-rezeptorantagonisten
EA200970581A1 (ru) Кристаллическое твёрдое основание разагилина
NO20074544L (no) Inhibering av HER2-losriving med matriksmetalloproteaseantagonister
NO20090295L (no) Substituerte heteroarylderivater
NO20083895L (no) Anti-IGF-1R human monoklonalantibody formulering
ATE459620T1 (de) Benzimidazolthiophenverbindungen als plk- modulatoren
EA201170198A1 (ru) Фармацевтические композиции, содержащие лиганды рецептора дофамина
BR112013007457A8 (pt) Formulações farmacêuticas contendo rifaximina, processos para a sua obtenção e método de tratar doença intestinal
DE602006018713D1 (de) Als agonisten für den nikotinischen acetylcholinrezeptor geeignete azabicycloalkanderivate
EA201000814A1 (ru) 5-[(3,3,3-трифтор-2-гидрокси-1-арилпропил)амино]-1h-хинолин-2-оны, способ их получения и их применение в качестве противовоспалительных средств
WO2008043052A3 (en) Human antibodies neutralizing human metapneumovirus
PL1888514T3 (pl) Sole podstawionych estrów kwasu alofanowego i ich zastosowanie w środkach leczniczych
WO2009124294A3 (en) Pharmaceutical compositions for binding sphingosine-1-phosphate
DE602005007765D1 (de) Neue indol- oder benzimidazol-derivate
MY157425A (en) Substituted oxindole derivatives and the use thereof for the treatment of vasopressin-dependent illnesses
NO20080441L (no) Benzofuranonderivater som ikke-steroide progesteronreseptormodulatorer
WO2009071691A3 (de) Oxindol-derivate und ihre verwendung als medikament
UY28828A1 (es) Nueva forma cristalina de ácido 8-ciano-1-ciclopropil-7-(1s, 6s-2,8-diazabiciclo(4.3.0)nonan-8-il)-6-fluoro-1,4-dihidro-4-oxo-3-quinolincarboxílico
ATE448215T1 (de) Selektive östrogen-rezeptor-modulatoren

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 10A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2289 DE 18/11/2014.